Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Potent and selective PAF antagonist from Uriach

Nov. 21, 1996

TBC-11251 enters clinical trials

Nov. 20, 1996

Completion of phase IIa trials with CytoTAb in sepsis

Nov. 19, 1996

ET antagonists revealed by SmithKline Beecham

Nov. 19, 1996

Hyal and The Hospital for Sick Children vascular disease collaboration

Nov. 15, 1996

Cypros acquires well-established Rx for esophageal varices

Nov. 15, 1996

Human pharmacokinetic/pharmacodynamic studies on bosentan

Nov. 15, 1996

NEP and ECE inhibitors reported by Kali-Chemie

Nov. 15, 1996

Clinical trials update on nibentan, Russian antiarrhythmic drug

Nov. 15, 1996

Chugai discloses antiischemic agents

Nov. 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...